Ocugen’s COVID-19 co-vaccine development partner, Bharat Biotech, shares second interim results that include 100% protection against serious diseases, including hospitalization
Fact diseases and conditions reported according to the yellow card scheme are not confirmed adverse reactions to vaccines
Fact-checking diseases and conditions reported according to the yellow card scheme are not confirmed adverse reactions to vaccines
Medicines against autoimmune diseases may reduce the vaccine response Antibody treatments ineffective against Brazil variant
Medicines against autoimmune diseases may reduce the vaccine response Antibody treatments ineffective against Brazil variant